December 20, 2023

Kory Wentworth Chief Financial Officer Entrada Therapeutics, Inc. One Design Center Place Suite 17-500 Boston, MA 02210

Re: Entrada

Therapeutics, Inc.

Fiscal Year Ended December 31, 2022

Form 10-K for the

Filed March 6, 2023 File No. 001-40969

Dear Kory Wentworth:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance

Office of Life Sciences